Svetoslava Elefterova Slavcheva

Dr. Svetoslava Elefterova Slavcheva

Medical University "Prof. Dr. Paraskev Stoyanov” Varna, Bulgaria.
orcid

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
Verified
Journal Article
Open access
PDF file
SSSvetoslava Elefterova Slavcheva
Svetoslava Elefterova Slavcheva
AAAtanas Angelov
Atanas Angelov
Trastuzumab is the primary treatment for all stages of HER2-overexpressing breast cancer in patients. Though discovered over 20 years ago, trastuzumab-induced cardiotoxicity (TIC) remains a research topic in cardio-oncology. This review explores the pathophysiological basis of TIC and its clinical manifestations. Their understanding is paramount for early detection and cardioprotective treatment. Trastuzumab renders cardiomyocytes susceptible by inhibiting the cardioprotective NRG-1/HER2/HER4 signaling pathway. The drug acts on HER2-receptor-expressing cardiomyocytes, endothelium, and cardiac progenitor cells (see the Graphical Abstract). The activation of immune cells, fibroblasts, inflammation, and neurohormonal systems all contribute to the evolution of TIC. A substantial amount of research demonstrates that trastuzumab induces overt and subclinical left ventricular (LV) systolic failure. Data suggest the development of right ventricular damage, LV diastolic dysfunction, and heart failure with preserved ejection fraction. Further research is needed to define a chronological sequence of cardiac impairments to guide the proper timing of cardioprotection implementation.

21 September 2021 in Current Oncology
Verified
Journal Article
Open access
PDF file
SSStanislav Slavchev
Stanislav Slavchev
YKYavor Kornovski
Yavor Kornovski
angel yordanovangel yordanov
angel yordanov
YIYonka Ivanova
Yonka Ivanova
Stoyan KostovStoyan Kostov
Stoyan Kostov
SSSvetoslava Elefterova Slavcheva
Svetoslava Elefterova Slavcheva
Background: Ovarian carcinoma (OC) is usually diagnosed at an advanced stage, necessitating a multimodal approach that includes surgery and systemic therapy. The incidence of OC is approximately five times higher in women over 65 years of age. Cardiovascular comorbidities and type 2 diabetes mellitus, both prevalent at this age, can influence therapeutic strategy and have an adverse effect on survival. Objectives: Our study aimed to determine the impact of cardiovascular diseases and diabetes mellitus on survival in advanced ovarian cancer. Materials and methods: From 2004 to 2012, we retrospectively studied 104 patients with advanced epithelial ovarian cancer (FIGO stage II–IV) who underwent surgical treatment at the Gynecology Clinic, St. Anna University Hospital, Varna, Bulgaria. Patients were followed for an average of 90 (52–129) months. We divided the study population into two groups: those with concurrent cardiovascular diseases and type 2 diabetes mellitus (CVD) and those without these comorbidities (No-CVD group). Overall survival (OS), disease-specific survival (DSS), and disease-free survival (DFS) were compared between groups using Kaplan–Meier survival analysis. Cardiovascular comorbidities and diabetes mellitus were evaluated for their prognostic value for survival using multivariate Cox proportional regression analysis adjusted for age, stage of OC, grade and histological type of the tumor, ascites presence, residual tumor size (RT), performance status, and type of hysterectomy. Results: The Kaplan–Meier analysis showed reduced OS and DSS in the CVD group compared to the No-CVD group. The median OS was 24.5 months (95% CI 18.38 months) and 38 months (95% CI 26, not reached), respectively (Log-rank p = 0.045). The median DSS was 25.5 months (95% CI 19.39 months) and 48 months (95% CI 28, not reached), respectively (Log-rank p = 0.033). The Cox regression multivariate analysis established a lower (by 68%) overall survival rate for the CVD patient group than the No-CVD group, approaching statistical significance (HR 1.68, 95% CI 0.99, 2.86, p = 0.055). Cardiovascular diseases and diabetes were associated with a 79% reduction in DSS (HR 1.79, 95% CI 1.02, 3.13, p = 0.041) and a twofold increase in the risk of disease progression (HR 2.05, 95% CI 1.25, 3.37, p = 0.005). Conclusions: According to our study, cardiovascular comorbidities and diabetes may adversely affect OC survival. Optimal control of cardiovascular diseases, diabetes mellitus, and their risk factors may be beneficial for patients with advanced OC. Further research involving a larger patient population is necessary to establish these comorbidities as independent prognostic factors.

24 October 2025 in Medicina
Verified
Journal Article
Open access
PDF file
SSSvetoslava Elefterova Slavcheva
Svetoslava Elefterova Slavcheva
SSSevim Shefket
Sevim Shefket
YBYana Bocheva
Yana Bocheva
AAAtanas Angelov
Atanas Angelov
Background and Objectives: Cardiac injury caused by cancer therapy can be detected early using high-sensitivity cardiac troponins (hs-cTns), and this is crucial for preventing irreversible consequences. Clinically relevant issues regarding hs-cTns in oncologic settings—such as reliable cut-off values, the optimal assessment timeframe, factors influencing their levels, and their prognostic ability in relation to functional echocardiographic parameters—require further investigation. In this study, we aimed to examine the determinants of hs-cTnT variations during cancer therapy and the relationship between the biomarker and functional conventional echocardiographic parameters. Materials and Methods: We prospectively evaluated adult patients scheduled for chemotherapy for either breast or gastrointestinal cancers, excluding those with pulmonary and cardiac disorders. We enrolled 40 patients who underwent a minimum of one cycle of potentially cardiotoxic regimens containing at least one of the following agents: anthracyclines, cyclophosphamide, taxanes, 5-fluorouracil, platinum compounds, trastuzumab, or bevacizumab. We observed two-dimensional and tissue Doppler echocardiographic parameters and hs-cTnT levels for a median of 360 days (IQR 162, 478) following the start of chemotherapy. Results: The generalised estimating equation (GEE) analysis revealed significant elevations in hs-cTnT levels at three months (β = 1.2; p = 0.005) and six months (β = 2.3; p = 0.02) from baseline, influenced by anthracycline treatment (p = 0.009), renal function (p = 0.003), and increased cardiotoxicity risk (high: p = 0.013; medium: p < 0.001). Elevated hs-cTnT levels independently predicted the deterioration of the LV longitudinal myocardial function, measured by the systolic tissue velocities, according to the GEE analysis. The receiver operating characteristic curve-derived hs-cTnT thresholds—of 8.23 ng/L and 8.08 ng/L—had a high negative predictive value for identifying Average and Lateral LVS′ decreases, respectively. Conclusions: Our research supports the use of baseline and continuing hs-cTnT testing in cancer patients, showing the dependence of the biomarker on renal function, cardiovascular toxicity risk level, and anthracycline treatment. The hs-cTnT cut-off value of approximately 8 ng/L may suggest a low probability of longitudinal myocardial function impairment and this observation needs further validation in larger cohorts.

25 March 2024 in Pharmacia
Verified
Journal Article
Open access
PDF file
SSSavi Shishkov
Savi Shishkov
KHKiril Hristozov
Kiril Hristozov
AAAtanas Angelov
Atanas Angelov
SSSvetoslava Elefterova Slavcheva
Svetoslava Elefterova Slavcheva
YBYana Bocheva
Yana Bocheva
MBMila Boyadzhieva
Mila Boyadzhieva
The role of androgens and estrogens in cardiovascular disease is a subject of ongoing studies. Therefore, we aim to explore the association of testosterone (T), estradiol and their ratio with cardiovascular risk factors and severity of cardiac ischemia in male patients with acute coronary syndrome. (ACS) n = 72 and controls (n = 35) Lower values of both total and free T were found in the ACS group compared to controls (8.97 vs. 10.98 nmol/l, p = 0.001 for total T and 0.189 vs. 0.223 nmol/l, p = 0.006 for free T). Patients with myocardial infarction with ST-elevation had significantly lower T fractions compared to ACS without ST-elevation. The T to estradiol ratio was significantly lower in the ACS group compared to controls and is lowest in those with STEMI. Also, all testosterone fractions – free, bioavailable, and free T, are lower in patients with ACS compared to controls. Based on these observations a conclusion can be drawn that amore estrogenic environment is associated with ST-elevation and correlates with the severity of ACS in male patients.

16 May 2024 in Bulgarian Cardiology
Verified
Journal Article
Open access
PDF file
SSSvetoslava Elefterova Slavcheva
Svetoslava Elefterova Slavcheva
Антрациклин-индуцираната кардиотоксичност (АИК) е позната от 70-те години на XX век, но продължава да е актуална, основно заради широкото приложение на антрациклините в онкологичната практика. Понастоящем АИК се разглежда като продължителен и непрекъснат процес, който започва още с първата доза на молекулно и клетъчно нива и еволюира в кардиомиопатия и сърдечна недостатъчност. Съвременните изследвания са насочени за откриване на методи за ранна детекция на антрациклин-свързаната миокардна увреда. В допълнение, разработват се средства за първична превенция на АИК, като се търси тяхната ефективност, мястото и времето на приложение. Целта на настоящия обзор да се представят наличните превантивни възможности, както и механизмите на тяхното действие и механизмите на АИК. Според съвременните препоръки на първична превенция подлежат пациентите с висок и много висок риск и тя включва общи мерки за понижение на сърдечно-съдовия риск, невро-хормонална терапия и статини. Периодичната кардиологична оценка е задължителна част от профилактиката на прогресията на сърдечната увреда. Установяване на лека миокардна увреда (влошен глобален надлъжен стрейн и освобождаване на тропонин) дава основание за кардиопротективна намеса. Някои въпроси в превенцията на АИК като ползата от по-ранна кардиопротекция, мястото и ефективността на сакубитрил/валсартан и на инхибиторите на натриево-глюкозния котранспортер 2 (SGLT2 инхибитори) са обект на бъдещи изследвания. Физическата активност изглежда обещаващ метод за намаляване на сърдечните увреждащи ефекти на антрациклините. Anthracycline-induced cardiotoxicity (AIC) has been known since the 1970s but remains relevant, mainly due to the widespread use of anthracyclines in oncological practice. Currently, AIC is viewed as a prolonged and continuous process that starts with the initial dose at molecular and cellular levels and advances, ultimately resulting in cardiomyopathy and heart failure. Many contemporary studies aim to discover methods for early detection of anthracycline-related myocardial injury. Additionally, ongoing research focuses on agents for primary prevention of AIC, examining their effectiveness, place, and timing of administration. This review aims to present the available preventive options, interconnecting them with their mechanisms of action and the mechanisms of AIC. According to current recommendations, primary prevention is indicated for high- and very high-risk patients and includes general measures to lower cardiovascular risk, neurohormonal therapy, and statins. Regular cardiology assessments are a crucial component of heart damage prevention. Evidence of mild myocardial injury (deteriorated Global Longitudinal Strain and troponin release) justifi es cardioprotective measures. Some aspects remain unanswered, including whether early cardioprotection is required, as well as the role and effi cacy of sacubitril/valsartan and sodium-glucose cotransporter 2 inhibitors (SGLT2 inhibitors) for AIC prevention. Physical activity is a promising method to reduce the cardiac damaging effects of anthracyclines.

21 July 2021 in Bulgarian Cardiology
Verified
Journal Article
Open access
PDF file
ZMZhenya Marinova
Zhenya Marinova
SSSvetoslava Elefterova Slavcheva
Svetoslava Elefterova Slavcheva
AAAtanas Angelov
Atanas Angelov
VVVeselin Valkov
Veselin Valkov
ВMВеселин Вълков Zhenya Marinova
Веселин Вълков Zhenya Marinova
We present a case of a 75-year-old male who underwent percutaneous coronary intervention in the setting of acute myocardial infarction with ST-segment elevation and who was hospitalized 12 days afterwards with COVID-19 pneumonia. Later the patient presented himself again with acute coronary syndrome with ST-segment elevation in the same region due to in-stent thrombosis. Transient atrioventricular conduction disorders were registered before and after the percutaneous coronary intervention. Possible pathophysiological mechanisms of the in-stent thrombosis following COVID-19 infection are discussed.